Daiwa Corporate Investment

What Daiwa Corporate Investment does

Daiwa Corporate Investment Co., Ltd. (DCI) is the venture capital and private equity arm of Daiwa Securities Group, headquartered in Marunouchi, Tokyo. Founded in 1982 as Nippon Investment & Finance (one of Japan's earliest VC firms) and rebranded to its current name in 2010, DCI has invested in 2,369 companies across 92 funds, achieved 672 portfolio IPOs, and deployed approximately ¥4,700 billion cumulatively as of March 2025. The firm operates a fund management business targeting institutional limited partners (pension funds, insurance companies, corporate investors) through private placement, earning revenue from fund management fees (up to ~3% per annum of committed capital) and carried interest (up to ~20% above hurdle).

DCI runs a horizontal segmentation strategy across geographies and verticals. In Japan, it backs growth-stage startups through the DCI Venture Growth Fund series and operates DCI Partners, a wholly-owned biotech-focused subsidiary managing ~¥26.9 billion across the Daiwa Taiwan-Japan BioVenture Fund I (¥11.6 billion, 2015) and Fund II (¥15.3 billion, 2020). Overseas, it runs the DAIWA-SSIAM Vietnam Growth Fund series (four generations, Fund IV launched in 2025) in partnership with SSI Asset Management, and the Hubei Tong Ying Equity Investment Fund series in China with Jointown Pharmaceutical Group and CECEP. Dedicated representative offices in Taipei, Ho Chi Minh City, and Wuhan support cross-border deal sourcing and portfolio operations. Subsidiaries Daiwa PI Partners (growth/turnaround) and Daiwa Energy & Infrastructure (renewable energy/infrastructure) extend the platform into adjacent alternative asset classes.

The firm's primary go-to-market is institutional fundraising through direct relationship management, complemented by top-of-funnel deal sourcing via the Daiwa Securities Group branch network, industry conferences (Bio Taiwan, JAXA Space Strategy Fund reviews, Vietnam Venture Summits), and thought-leadership columns in Nikkei Biotechnology & Business. Portfolio companies receive hands-on IPO advisory, M&A guidance, and follow-on capital via the parent securities group, forming a closed-loop alternative asset platform under the Daiwa Investment Management holding entity.

Name

Daiwa Corporate Investment

Legal name

Daiwa Corporate Investment Co., Ltd.

Website

https://daiwa-inv.co.jp

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Daiwa Corporate Investment is the venture capital and private equity arm of Daiwa Securities Group, managing 92 funds with approximately ¥4,700 billion in cumulative investments across Japan, Vietnam, China, and Taiwan for institutional limited partners.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Equity Fund Management

NAICS

All Other Financial Investment Activities (52399), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds (FSANAGAC)

akta.pro secondary industries

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN), Venture Growth / Recurring Revenue Credit Funds (FSANAIAG)

Keywords

• Venture capital management
• Private equity funds
• Biotech investment
• Startup growth capital
• Cross-border investments

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Fund Management Fees: DCI earns management fees from the funds it operates, typically calculated as a percentage of committed capital under management (e.g., up to 3% per annum of total committed capital), charged throughout the fund's investment period to liquidation.
2. Carried Interest (Success Fees): DCI earns performance-based carried interest from fund investments, typically up to 20% of capital gains realized above the hurdle rate, paid upon successful exits (IPOs, M&A).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Daiwa Corporate Investment manages venture capital and private equity funds that invest in startups and growth-stage companies across Japan and Asia (Vietnam, China, Taiwan). The firm raises capital from institutional investors and deploys it into unlisted companies, generating returns through capital gains on exits (IPOs, M&A) while charging management fees and carried interest. Core fund franchises include the DAIWA-SSIAM Vietnam Growth Fund series, DCI Venture Growth Funds, Daiwa Taiwan-Japan BioVenture Funds, and Hubei Tong Ying Funds, with a dedicated biotech subsidiary (DCI Partners).

Product overview

Daiwa Corporate Investment (DCI) is a venture capital firm and subsidiary of Daiwa Securities Group, providing fund investment and management services. The firm operates multiple investment funds across Asia, including Vietnam, China, and Taiwan, with a focus on startups and emerging companies. The company also maintains a biotech-focused subsidiary called DCI Partners that manages life science funds investing in drug discovery and regenerative medicine companies in Japan and Taiwan. Key fund products include the DAIWA-SSIAM Vietnam Growth Fund series, Hubei Tong Ying Equity Investment Funds, DCI Venture Growth Funds, and the Daiwa Taiwan-Japan BioVenture Investment series. The firm leverages Daiwa Securities Group's 120+ year history, extensive branch network, and corporate relationships to support portfolio companies through IPO and M&A processes.

Differentiator

Problem solved

Functional benefit

Brands

• DCI Partners: Biotechnology-focused venture capital subsidiary specializing in drug discovery and regenerative medicine investments in Japan and Taiwan, managing approximately 26.9 billion JPY across multiple funds.
• DCI Venture Growth Fund
• DAIWA-SSIAM Vietnam Growth Fund

Products and services

• DAIWA-SSIAM Vietnam Growth Fund Series Vietnam-focused closed-end private equity fund series co-managed with SSI Asset Management, deploying capital into Vietnamese small-to-midsize companies and listed equities (PIPEs) benefiting from rising middle class and lifestyle shifts. Available to institutional LPs via private placement.
• DCI Venture Growth Fund Series Growth-stage venture capital funds providing expansion capital and hands-on support to Japanese startups with unique technologies and business models across sectors including deep tech, space, energy, and medical fields. Available to institutional LPs via private placement.
• Daiwa Taiwan-Japan BioVenture Investment Limited Partnership (Funds I & II) Biotechnology-focused venture capital funds managed by DCI Partners, providing capital and specialized operational support to unlisted drug discovery and regenerative medicine startups in Japan and Taiwan. Fund I closed at 11.6 billion JPY; Fund II reached 15.3 billion JPY. Cumulative fund size across DCI Partners: approximately 26.9 billion JPY. Available to institutional LPs via private placement.
• Hubei Tong Ying Equity Investment Fund Series China-focused equity investment funds targeting healthcare, consumption, and environmental sectors in Hubei province and the broader Chinese market. Available to institutional LPs via private placement.
• CECEP Hubei SDG Industry Equity Investment Fund China-focused private equity fund investing in eco-friendly and sustainable development sectors across China's Yangtze River Economic Belt. Available to institutional LPs via private placement.

Quantifiable outcome

• 672 IPOs achieved by portfolio companies
• +4 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• SSI Asset Management (SSIAM)coreStrategic or Co-development Partner · 12 May 2026SSIAM, a subsidiary of SSI Securities (Vietnam's largest securities company), partnered with DCI and CCI CrossBorder to jointly source, structure, and execute medium and long-term investment and financing opportunities for Vietnamese enterprises, particularly in manufacturing and industrial sectors. The partnership expands the existing Daiwa-SSIAM Vietnam Growth Fund series (Funds I through III already in place, Fund IV announced in 2025), and will include diversified capital solutions such as credit and mezzanine financing.
• CCI CrossBorder (CCIX)coreStrategic or Co-development Partner · 12 May 2026CCI CrossBorder (CCIX), a cross-border investment advisory firm, signed a strategic MoU with SSIAM and DCI to jointly create and expand co-investment and co-financing opportunities in Vietnam, facilitating connections between Vietnamese companies and Japanese investors.
• Orient Commercial Joint Stock Bank (OCB)coreStrategic or Co-development Partner · 1 April 2026DCI signed a strategic MoU with OCB, a Vietnamese commercial bank, to contribute to the growth and corporate value enhancement of DCI's portfolio companies in the Vietnamese market, leveraging OCB's local banking network and financial services.
• Jointown Pharmaceutical GroupcoreStrategic or Co-development PartnerJointown Pharmaceutical Group, China's largest private pharmaceutical distributor, co-formed the Hubei Tong Ying Equity Investment Fund II with DCI to invest in China's healthcare and consumer sectors, supported by the Hubei provincial government.
• China Energy Conservation and Environmental Protection Group (CECEP)coreStrategic or Co-development PartnerDCI partnered with CECEP (a Chinese state-owned environmental group) and local partners (Hubei Provincial High Technology Investment, Changjiang River Venture Capital) to form the CECEP Hubei SDG Industry Equity Investment Fund, investing in eco-friendly sectors across China's Yangtze River Economic Belt.
• SSI Asset Management (SSIAM) — Fund PartnershipcoreStrategic or Co-development PartnerDCI and SSIAM have co-managed four generations of the DAIWA-SSIAM Vietnam Growth Fund series (Fund I launched 2015, Fund II 2016, Fund III 2020, Fund IV 2025), investing in Vietnamese companies across retail, consumer, manufacturing, healthcare, and infrastructure sectors.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• JAFCO Group: Japan's largest independent venture capital and buyout firm with similar focus on early-to-growth stage domestic investments and IPO-oriented exits. Directly comparable in product (VC fund management), customer base (Japanese institutional LPs), and exit strategy (Tokyo Stock Exchange IPOs).
• SBI Investment: Major Japanese VC firm operating multiple sector-focused funds with strong focus on domestic startups and biotech/fintech verticals. Directly comparable as a large-scale Japanese VC managing diversified fund products with similar institutional LP base.
• Global Brain: Tokyo-based VC firm with deep-tech and cross-border Japan-US focus, managing multiple sector-specific funds. Comparable in product (sector-focused VC fund management) and target customer (Japanese institutional LPs seeking diversified exposure).
• Nissay Capital: Japanese corporate venture capital firm affiliated with Nippon Life Insurance, investing across early-to-mid stage startups. Directly comparable as a Japanese CVC fund manager with similar institutional LP base and recent co-investment activity alongside DCI in Series A rounds.
• World Innovation Lab (WiL): Japan-based cross-border venture firm operating between Japan, Silicon Valley, and Asia. Comparable in international investment mandate and Japanese LP base, though with stronger US presence than DCI.
• Vertex Ventures: Singapore-headquartered VC network with funds across Southeast Asia, China, Japan, and Israel. Comparable as a multi-geography Asian VC platform managing sector and country-specific funds with institutional LPs.
• Vickers Venture Partners: Asia-focused early-to-growth stage VC firm investing across Southeast Asia, China, and Japan. Comparable in cross-border Asian VC mandate and biotech/sci-tech sector exposure.
• Daiwa PI Partners: Wholly-owned DCI subsidiary focused on growth-to-turnaround investments using diverse methodologies. Most directly comparable as a sister entity sharing the same parent (Daiwa Securities Group) and overlapping institutional LP base.

Regional players

• Mekong Capital: Vietnam-focused PE/VC firm with a long-tenured track record investing in Vietnamese consumer and retail companies. Directly comparable as a regional Vietnam-focused fund manager targeting Japanese LP co-investment relationships.

Broad incumbents

• Daiwa Energy & Infrastructure: Wholly-owned DCI subsidiary investing in renewable energy and infrastructure. Comparable as a sister DCI entity sharing the Daiwa Securities Group parent and alternative asset investment strategy, though with infrastructure rather than venture focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/daiwa

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments148 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiwa Corporate Investment